Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence
NCT ID: NCT00218075
Last Updated: 2016-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
200 participants
INTERVENTIONAL
2000-03-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence
NCT00713583
Medications for Stopping Cocaine Dependence and Preventing Relapse
NCT00218023
A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use
NCT02444208
Cognitive Remediation for Cocaine Dependence
NCT01393457
Effectiveness of Extended Treatments for Drug Dependence
NCT00685659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will last 12 weeks and will involve two phases. The first phase will include three therapy conditions: 1) clinical management only, 2) clinical management and relapse prevention therapy, and 3) clinical management, relapse prevention therapy, and contingency management. All of the conditions in the first phase will be evaluated incrementally under active and placebo conditions while participants receive carbidopa/levodopa.
The second phase of the study will examine the contingency management procedure applications. Each of the three contingency management procedure applications targets specific behaviors that, when reinforced, may interact with carbidopa/levodopa to produce clinical benefits. Participants will receive relapse prevention therapy combined with a contingency management procedure that targets clinic attendance, medication compliance, and cocaine abstinence. Study visits will occur weekly throughout the study. In addition, participants will complete a one-year follow-up visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levodopa
Carbidopa
Clinical Management
Relapse Prevention Therapy
Contingency Management
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provides at least one positive urine test for cocaine during study screening
* Good general health, based on a physical exam, lab tests, and an electrocardiogram
* Reads and writes English at a sixth grade level
Exclusion Criteria
* Currently in jail
* Pregnant or breastfeeding
* Requires certain medications
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
University of Texas
OTHER
The University of Texas Health Science Center, Houston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joy Schmitz
Professor - Psy, Behavioral Science
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Grabowski, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Texas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas Health Science Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P50-09262-9
Identifier Type: -
Identifier Source: secondary_id
DPMC
Identifier Type: -
Identifier Source: secondary_id
NIDA-09262-9
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.